Amgen (MEX:AMG N) Tariff Resilience Score : 7/10 (As of Jul. 07, 2025)

View and export this data going back to 2004. Start your Free Trial

What is Amgen Tariff Resilience Score?

Amgen has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Amgen has Amgen's global pharmaceutical operations face moderate tariff exposure, primarily on raw materials. The company has managed past impacts through strategic sourcing and pricing power. Industry-specific exemptions provide some protection, enhancing resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Amgen might have Highly Resilient.

Competitive Comparison of Amgen's Tariff Resilience Score

For the Drug Manufacturers - General subindustry, Amgen's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's Tariff Resilience Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Amgen's Tariff Resilience Score falls into.

Save Embed

;

Save Embed

;

Amgen (MEX:AMG N) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score	Resilience Level
7 - 10	Highly Resilient
4 - 6	Average Resilient
0 - 3	Highly Vulnerable

Amgen Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Amgen's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (MEX:AMG N) » Definitions » Tariff Resilience Score

Comparable Companies

Traded in Other Exchanges

AMGN:USA 1AMGN:Italy AMGd:UK 0R0T:UK AMG:Germany AMGN:Canada AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines